Actinium Pharmaceuticals, Inc. (ATNM)
Automate Your Wheel Strategy on ATNM
With Tiblio's Option Bot, you can configure your own wheel strategy including ATNM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ATNM
- Rev/Share 0.0
- Book/Share 0.8236
- PB 2.0519
- Debt/Equity 0.0558
- CurrentRatio 9.3468
- ROIC -0.7913
- MktCap 52721071.0
- FreeCF/Share -1.0666
- PFCF -1.5845
- PE -1.1584
- Debt/Assets 0.0209
- DivYield 0
- ROE -1.2957
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Research Annual Meeting
Published: April 28, 2025 by: PRNewsWire
Sentiment: Neutral
Actimab-A significantly potentiated and prolonged efficacy in combination with standard of care targeted therapies including hypomethylating agent azacitidine, FLT3 and menin inhibitors in in-vivo AML models Actimab-A is the only CD33 targeted radiotherapy with Actinium-225 isotope payload in development for AML and other myeloid malignancies Actimab-A is currently being advanced in several combination studies including a Phase 2/3 trial in combination with CLAG-M in relapsed/refractory AML and in combination with Venetoclax and ASTX-727, an oral hypomethylating agent from Taiho Oncology in frontline AML under a CRADA with the NCI NEW YORK , April 28, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. …
Read More
May 27, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against ATNM
Published: April 28, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , April 28, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Actinium Pharmaceuticals, Inc. (NYSE: ATNM). Shareholders who purchased shares of ATNM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium
Published: April 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Actinium To Contact Him Directly To Discuss Their Options
Read More
Levi & Korsinsky Reminds Actinium Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 27, 2025 - ATNM
Published: April 25, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 25, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=145149&wire=1 or contact Joseph E. Levi, Esq.
Read More
ATNM Investors Have the Opportunity to Lead the Actinium Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
Published: April 25, 2025 by: Accesswire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Actinium To Contact Him Directly To Discuss Their Options NEW YORK CITY, NY / ACCESS Newswire / April 25, 2025 / If you suffered losses exceeding $75,000 in Actinium between October 31, 2022 and August 2, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against …
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
Published: April 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE: ATNM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
Published: April 22, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , April 22, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE: ATNM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
Class Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM) Seeking Recovery for Investors - Contact Levi & Korsinsky
Published: April 22, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 22, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=144448&wire=1 or contact Joseph E. Levi, Esq.
Read More
ATNM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Actinium Pharmaceuticals, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit!
Published: April 22, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / April 22, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE:ATNM) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Actinium securities between March 31, 2022 and August 2, 2024, both dates inclusive (the "Class Period").
Read More
Levi & Korsinsky Reminds Actinium Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 27, 2025 - ATNM
Published: April 22, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , April 22, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE: ATNM) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Actinium investors who were adversely affected by alleged securities fraud between October 31, 2022 and August 2, 2024.
Read More
Lost Money on Actinium Pharmaceuticals, Inc.(ATNM)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky
Published: April 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 21, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=144350&wire=1 or contact Joseph E. Levi, Esq.
Read More
ROSEN, A LEADING LAW FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATNM
Published: April 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / April 21, 2025 / WHY: New York, N.Y., April 21, 2025.
Read More
Lost Money on Actinium Pharmaceuticals, Inc. (ATNM)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
Published: April 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 21, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=144286&wire=1 or contact Joseph E. Levi, Esq.
Read More
Actinium Pharmaceuticals, Inc. Class Action: Levi & Korsinsky Reminds Actinium Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 27, 2025 – ATNM
Published: April 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE: ATNM) of a class action securities lawsuit.
Read More
May 27, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ATNM
Published: April 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 21, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=144195&wire=1 or contact Joseph E. Levi, Esq.
Read More
ATNM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Actinium Pharmaceuticals, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!
Published: April 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / April 21, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company") (NYSE:ATNM) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Actinium securities between March 31, 2022 and August 2, 2024, both dates inclusive (the "Class Period").
Read More
Class Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM) - May 27, 2025 Deadline to Join - Contact The Gross Law Firm
Published: April 21, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , April 21, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Actinium Pharmaceuticals, Inc. (NYSE: ATNM). Shareholders who purchased shares of ATNM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit - ATNM
Published: April 20, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 20, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=144140&wire=1 or contact Joseph E. Levi, Esq.
Read More
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATNM
Published: April 20, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 20, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) between October 31, 2022 and August 2, 2024, both dates inclusive (the "Class Period"), of the important May 26, 2025 lead plaintiff deadline. SO WHAT: If you purchased Actinium securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
Shareholders that lost money on Actinium Pharmaceuticals, Inc.(ATNM) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
Published: April 20, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 20, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=144107&wire=1 or contact Joseph E. Levi, Esq.
Read More
Levi & Korsinsky Reminds Actinium Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 27, 2025 - ATNM
Published: April 18, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 18, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=143930&wire=1 or contact Joseph E. Levi, Esq.
Read More
Actinium Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 27, 2025 to Discuss Your Rights – ATNM
Published: April 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, April 18, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE: ATNM) of a class action securities lawsuit.
Read More
ATNM LAWSUIT ALERT: Levi & Korsinsky Notifies Actinium Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Published: April 18, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 18, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=143899&wire=1 or contact Joseph E. Levi, Esq.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
Published: April 18, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 18, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE:ATNM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
Actinium Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before May 27, 2025 to Discuss Your Rights - ATNM
Published: April 16, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 16, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=143466&wire=1 or contact Joseph E. Levi, Esq.
Read More
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATNM
Published: April 16, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / April 16, 2025 / WHY: New York, N.Y., April 16, 2025.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
Published: April 16, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 16, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE:ATNM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
Levi & Korsinsky Reminds Actinium Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 27, 2025 - ATNM
Published: April 16, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 16, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=143392&wire=1 or contact Joseph E. Levi, Esq.
Read More
Ibotta, Inc. Investors: Company Investigated by the Portnoy Law Firm
Published: April 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
Investors can contact the law firm at no cost to learn more about recovering their losses
Read More
Investors in Actinium Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before May 27, 2025 to Discuss Your Rights - ATNM
Published: April 15, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 15, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=143157&wire=1 or contact Joseph E. Levi, Esq.
Read More
About Actinium Pharmaceuticals, Inc. (ATNM)
- IPO Date 2012-12-27
- Website https://www.actiniumpharma.com
- Industry Biotechnology
- CEO Mr. Sandesh C. Seth M.B.A., M.S.
- Employees 31